Cinaciguat

Cinaciguat is an activator of guanylate cyclase (sGC), and used for acute decompensated heart failure.

Product Specifications

CAS Number

[329773-35-5]

Product Name Alternative

BAY 58-2667

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Guanylate Cyclase

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Cinaciguat.html

Concentration

10mM

Purity

99.15

Solubility

DMSO : ≥ 50 mg/mL

Smiles

OC(C(C=C1)=CC=C1CN(CCCCC(O)=O)CCC(C=CC=C2)=C2OCC(C=C3)=CC=C3CCC4=CC=CC=C4)=O

Molecular Formula

C36H39NO5

Molecular Weight

565.70

Precautions

H302, H315, H319, H335

References & Citations

[1]Mátyás C, et al. The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus. Cardiovasc Diabetol. 2015 Oct 31;14:145.|[2]Reinke Y, et al. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats. Format: AbstractSend to Eur J Pharmaco|[3]Cosyns SM, et al. Influence of cinaciguat on gastrointestinal motility in apo-sGC mice. Neurogastroenterol Motil. 2014 Nov;26 (11) :1573-85.